HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

dusquetide

an innate defense regulator that targets p62 protein; SGX94 is the acetate salt

Also Known As:

SGX94 peptide

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - dusquetide: 2

Experts

1.	Adkins, Douglas: 2 articles (09/2017 - 12/2016)
2.	Azawi, Samar: 2 articles (09/2017 - 12/2016)
3.	Bonomi, Marcelo: 2 articles (09/2017 - 12/2016)
4.	Donini, Oreola: 2 articles (09/2017 - 12/2016)
5.	Elder, Jenna: 2 articles (09/2017 - 12/2016)
6.	Katz, Sanford: 2 articles (09/2017 - 12/2016)
7.	Kudrimoti, Mahesh: 2 articles (09/2017 - 12/2016)
8.	Sonis, Stephen T: 2 articles (09/2017 - 12/2016)
9.	Straube, Richard: 2 articles (09/2017 - 12/2016)
10.	Worden, Francis: 2 articles (09/2017 - 12/2016)

Related Diseases

1.	Inflammation (Inflammations) 12/10/2016 - "Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at a key convergence point in intracellular signaling pathways and has demonstrated activity in both reducing inflammation and increasing clearance of bacterial infection. "
2.	Bacterial Infections (Bacterial Infection) 12/10/2016 - "Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at a key convergence point in intracellular signaling pathways and has demonstrated activity in both reducing inflammation and increasing clearance of bacterial infection. "
3.	Head and Neck Neoplasms (Head and Neck Cancer) 12/10/2016 - "Testing the hypothesis that dusquetide can mitigate the development and duration of OM, preclinical studies have been completed and correlated with interim results from a Phase 2 clinical study in patients undergoing CRT for head and neck cancer. " 09/01/2017 - "Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. " 09/01/2017 - "Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients."
4.	Stomatitis 09/01/2017 - "Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). " 12/10/2016 - "Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study." 09/01/2017 - "Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients."
5.	Neoplasms (Cancer) 09/01/2017 - "Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. " 09/01/2017 - "Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients."

Related Therapies and Procedures

1.	Therapeutics